Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.
FDA approves Genzyme’s AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing multiple sclerosis
Onset of psoriasis upon interferon beta treatment in a multiple sclerosis patient.
Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?
Flupirtine as Oral Treatment in Multiple Sclerosis (FLORIMS)
Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects.
Headache in relapse and remission phases of multiple sclerosis: A case-control study.
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
Teriflunomide in multiple sclerosis: Added benefit not proven
Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence.
Use of rituximab in multiple sclerosis: current progress and future perspectives.
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Newly onset sinus bradycardia in the context of multiple sclerosis relapse.
FGF-1 Triggers Pannexin-1 Hemichannel Opening in Spinal Astrocytes of Rodents and Promotes Inflammatory Responses in Acute Spinal Cord Slices.
Masitinib in Patients with Progressive or Relapse-Free Secondary Multiple Sclerosis
Immunopathology: autoimmune glial diseases and differentiation from multiple sclerosis.
Induction of a Unique Isoform of the NCOA7 Oxidation Resistance Gene by Interferon β-1b.
A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray.
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
EU regulator warns on possible MS drugs side effects
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment.
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Boxed warning of HBV risk added to Rituxan, Arezerra

Pages